Labarai masu kwanan watan Yuli 5, 2023. Kwanan nan, an fitar da "Jerin da ya fi tasiri a masana'antar harhada magunguna ta kasar Sin" a shekarar 2022-2023, wanda ya jawo hankalin masana'antar. MedGence ta lashe lambar yabo ta R&D mafi girma na 50 na kasar Sin a shekarar 2022-2023 da kuma lambar yabo ta masana'antar harhada magunguna ta kasar Sin ta shekarar 2022-2023, wanda ke nuna cewa masana'antun sun sake samun karbuwar karfin R&D na MedGence.
Kungiyar likitocin da masana'antu ta kasar Sin baki daya ta kaddamar da "Jerin masana'antun harhada magunguna mafi tasiri a kasar Sin" a shekarar 2014, wanda aka gudanar da shi tsawon zama 9 a jere ya zuwa yanzu. Tare da ƙwarewar da aka tara shekaru da yawa da kuma albarkatun masana'antu masu karfi, Ƙungiyar ta gayyaci ƙwararrun ƙwararrun gida na farko don kafa kwamitin zaɓi. Taron ya bi ka'idodin tarin buɗaɗɗen, bayanan haƙiƙa, ƙaƙƙarfan tantancewa, da zaɓi na gaskiya. Tare da haɗin gwiwar sanannun kafofin watsa labaru na cikin gida da yawa, ta zaɓi jerin mafi tasiri a cikin masana'antar harhada magunguna kuma ta zama aiki mai iko a masana'antar harhada magunguna ta kasar Sin.
Lokacin aikawa: Agusta-01-2023